Orexigen Therapeutics, Inc. (OREX) Reaches $0.39 Yearly Low; HINO MOTERS LTD ORD ORDINARY SHARES (HINOF) SI Decreased By 61.71%

March 12, 2018 - By Marie Mckinney

The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) hit a new 52-week low and has $0.36 target or 8.00% below today’s $0.39 share price. The 9 months bearish chart indicates high risk for the $7.44 million company. The 1-year low was reported on Mar, 12 by Barchart.com. If the $0.36 price target is reached, the company will be worth $595,040 less. The stock decreased 71.87% or $1.0062 during the last trading session, reaching $0.3938. About 4.81M shares traded or 812.04% up from the average. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has declined 15.00% since March 12, 2017 and is downtrending. It has underperformed by 31.70% the S&P500.

HINO MOTERS LTD ORD ORDINARY SHARES (OTCMKTS:HINOF) had a decrease of 61.71% in short interest. HINOF’s SI was 203,500 shares in March as released by FINRA. Its down 61.71% from 531,500 shares previously. With 1,000 avg volume, 204 days are for HINO MOTERS LTD ORD ORDINARY SHARES (OTCMKTS:HINOF)’s short sellers to cover HINOF’s short positions. It closed at $13.9 lastly. It is down 0.00% since March 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. The company has market cap of $7.44 million. It offers Contrave for the treatment of obesity. It currently has negative earnings. The firm also offers Contrave under the Mysimba brand name.

Analysts await Orexigen Therapeutics, Inc. (NASDAQ:OREX) to report earnings on March, 27. They expect $-2.06 earnings per share, up 22.85% or $0.61 from last year’s $-2.67 per share. After $-1.35 actual earnings per share reported by Orexigen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 52.59% negative EPS growth.

Among 5 analysts covering Orexigen Therapeutics (NASDAQ:OREX), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Orexigen Therapeutics had 12 analyst reports since August 5, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Overweight” rating in Tuesday, October 6 report. The rating was downgraded by Wells Fargo to “Market Perform” on Friday, December 4. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, November 6 report. Piper Jaffray maintained it with “Buy” rating and $21 target in Saturday, August 8 report. JMP Securities downgraded Orexigen Therapeutics, Inc. (NASDAQ:OREX) on Wednesday, March 16 to “Market Perform” rating. The company was maintained on Monday, August 10 by JP Morgan. Bank of America reinitiated Orexigen Therapeutics, Inc. (NASDAQ:OREX) on Friday, December 11 with “Underperform” rating. RBC Capital Markets upgraded Orexigen Therapeutics, Inc. (NASDAQ:OREX) rating on Tuesday, September 15. RBC Capital Markets has “” rating and $9 target. On Wednesday, August 5 the stock rating was upgraded by Zacks to “Sell”.

Hino Motors, Ltd. manufactures and sells large commercial vehicles under the Hino brand worldwide. The company has market cap of $7.19 billion. It offers trucks and buses; light-commercial vehicles; and passenger vehicles, as well as various types of engines, spare parts, etc. It has a 15.94 P/E ratio. The firm was founded in 1910 and is headquartered in Hino, Japan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: